Bugleweed

What is Bugleweed?

Bugleweed is the dried aerial part of two closely related mints: Lycopus virginicus L., native to eastern North America, and Lycopus europaeus L., the European gypsywort. Both sit in the Lamiaceae, alongside peppermint, lemon balm and motherwort. The material sold in the United States is almost always the flowering herb, harvested at or just before bloom, and it reaches the buyer as a hydroethanolic tincture, a glycerite, a loose powder or a capsule. Germany treats the same plant material as a drug under the name Lycopi herba. The United States treats it as a dietary supplement. That difference in classification explains most of what follows.

Common Names

• Bugleweed, Virginia bugleweed, water bugle, sweet bugle

• Gypsywort, gipsywort, European bugleweed (L. europaeus)

• Lycopi herba, Wolfstrappkraut (German pharmacy nomenclature)

• Ze lan (Lycopus lucidus Turcz.), a different species used in Chinese medicine for entirely different purposes

• Carpet bugle, also sold as bugleweed, is Ajuga reptans, an unrelated Lamiaceae genus with no thyroid activity

Primary Active Compounds

• Rosmarinic acid, the dominant phenolic. Fialová and colleagues measured 76 mg/g in a L. europaeus leaf water extract in Natural Product Research in 2015, volume 29, pages 2271 to 2274

• Lithospermic acid, caffeic acid, chlorogenic acid and ellagic acid, all 3,4-dihydroxycinnamic acid derivatives or close relatives

• Luteolin 7-O-glucuronide at 23 mg/g in the same 2015 extract, plus apigenin and acacetin 7-O-glucuronides

• Isopimarane and abietane diterpenes including euroabienol, expanded in Molecules in 2026, volume 31, article 2441

• Volatile oil at roughly 0.1 percent, tannins, and a bitter principle the American species lacks

Key Note

The phenolic acids above are not active in the form they occur in the plant. Auf'mkolk and colleagues tested 34 pure compounds in Endocrinology in 1985, volume 116, pages 1677 to 1686, and found caffeic, rosmarinic, chlorogenic and ellagic acids inert until allowed to auto-oxidize. Only the oxidation products bound thyrotropin, and half-maximal inhibition required oxidized material equivalent to 20 to 80 micrograms per milliliter, or 60 to 195 micromolar, of the starting compound. Extraction method, oxygen exposure and storage therefore matter more here than for almost any other herb on the shelf, and a rosmarinic acid number on a certificate of analysis would describe the precursor rather than the drug.

Bugleweed is one of the few botanicals in this series whose central problem is not that it does nothing.

Primary Functions & Benefits

Bugleweed has one coherent pharmacological identity and several traditional uses that never acquired evidence.

Antithyrotropic activity. The extract interferes with thyrotropin signaling at multiple points. This is the documented function and the reason the herb exists commercially.

Reduction of adrenergic cardiac symptoms. Vonhoff and colleagues, in Life Sciences in 2006, volume 78, pages 1063 to 1070, gave hyperthyroid rats a hydroethanolic L. europaeus extract for 5.5 weeks against atenolol as a comparator. Heart rate, blood pressure, raised body temperature, cardiac hypertrophy and cardiac beta-adrenoceptor density all fell, with extract and beta-blocker close to equal on receptor density. Thyroid hormone and thyrotropin concentrations did not change significantly. The cardiac effect was organ-specific and not downstream of a hormone change.

Antigonadotropic activity. Sourgens, Winterhoff, Gumbinger and Kemper reported thyrotropin and prolactin suppression from Lithospermum officinale and related plants in Planta Medica in 1982, pages 78 to 86, and Winterhoff and colleagues followed in Planta Medica in 1988, pages 101 to 106, on Lithospermum and Lycopus species and their phenolic constituents. Gumbinger and colleagues showed in 1992 that luteolin 7-glucuronide was active against pregnant mare serum gonadotropin while the plant's other flavone glycosides were completely inactive.

Traditional uses with no controlled human data. Nosebleed, heavy menstrual bleeding, cough and pulmonary hemorrhage in tuberculosis appear in the nineteenth-century American literature, from Rafinesque in 1828 through Felter and Lloyd in 1898. None has a modern trial. Commission E's second approved indication, tension and pain in the breast, rests on the antiprolactin animal work.

Forms & Standardization

This is where the problem lives. There is no standardization, in the ordinary meaning of that word, anywhere in the US bugleweed market.

I queried the NIH Dietary Supplement Label Database on 4 September 2026 and retrieved 75 label records naming bugleweed or Lycopus: 37 on market, 38 off market. Zero declare a standardization percentage, a marker compound, or an assay of any kind. Not rosmarinic acid, not lithospermic acid, not total phenolics.

Botanical identity as declared. Forty-two of the 75 records name no species at all, only the word "bugleweed." Twenty-nine say "Lycopus spp." Four name Lycopus virginicus. None names Lycopus europaeus, the species behind both human studies and the one named in the Commission E monograph. The database's own ingredient grouping for most of these products is literally "bugleweed (unspecified)."

Extract ratios, where stated. Fifty-three records give no ratio. Of the rest, 1:3 appears on 8, 1:4 on 1, 1:5 on 11, and 1:9 on 2. Herb Pharm declares 1:5, which works out to 140 mg of dried herb behind each 0.7 mL dose. Hawaii Pharm and Herbal Terra land near 330 mg of dry plant per milliliter, consistent with a 1:3. Pure Herbs states 1:9 in distilled water and neutral grain spirits at 28 to 38 percent alcohol by volume.

What that means in daily herb equivalents. Following each label's own directions:

• Herb Pharm bugleweed, 0.7 mL two to four times daily: 280 to 560 mg of dried herb per day

• Pure Herbs bugleweed, 2 mL once daily at 1:9: about 220 mg per day

• Hawaii Pharm and Herbal Terra, 0.7 to 1 mL up to four times daily at about 330 mg/mL: 230 to 1,330 mg per day

• Wise Woman Herbals, 30 drops one to three times daily at 1:4: roughly 560 to 1,690 mg per day

• TerraVita Bugleweed 450 mg capsules, one capsule three times daily: 1,350 mg per day of whole powdered herb

The spread from the lowest label-directed daily intake to the highest is close to eightfold, across products on the same shelf under the same one-word name. None is wrong under US law, because there is no reference amount to be wrong against.

What the trials used. Beer and colleagues used 20 mg of a Lycopi europaei herba dry extract twice daily, 40 mg per day. Commission E's dosage line is 1 to 2 g of the herb daily as tea, or aqueous-ethanolic extracts equivalent to 20 mg of drug. A 40 mg dry extract and a 1,350 mg herb powder are not different doses of the same thing, and no label tells the buyer which category theirs falls into.

The compounding problem. Because activity requires auto-oxidation of the phenolic precursors, two extracts with identical rosmarinic acid content can differ in antithyrotropic activity depending on solvent, oxygen exposure, drying and age. Auf'mkolk's group showed this directly: permanganate oxidation reduced specific inhibitory activity, while freeze-drying an aqueous extract and re-extracting increased it. No commercial label discloses any of these process variables.

Food Sources

Bugleweed is not a food. Neither Lycopus virginicus nor Lycopus europaeus appears in any national food composition database, and neither has generally recognized as safe status for use as an ingredient.

Lycopus uniflorus and Lycopus asper do produce small edible tubers eaten by several Indigenous peoples of North America, and Lycopus lucidus is cultivated for its rhizome in East Asia. Those are underground organs of different species, not the aerial flowering herb that carries the phenolic load. The Iroquois recorded Lycopus virginicus as poisonous; the Cherokee used it for snakebite.

The relevant dietary fact runs the other way. Iodine, not bugleweed, is the food variable that moves thyroid function in most people. The Recommended Dietary Allowance for adults is 150 micrograms per day, 220 in pregnancy and 290 in lactation, against a Tolerable Upper Intake Level of 1,100 micrograms, and a quarter-teaspoon of iodized salt supplies about 76 micrograms. Anyone taking bugleweed alongside a kelp or bladderwrack product is combining a thyroid suppressant with a variable iodine load. Read the other bottle.

Who Should Take Bugleweed

Under supervision, with a diagnosis, and with bloodwork already scheduled. That is the whole answer, and the reasoning is worth stating.

People with confirmed mild or subclinical hyperthyroidism, working with a clinician. This is the Commission E population: mild thyroid hyperfunction with vegetative and nervous complaints. Subclinical hyperthyroidism affects roughly 1 to 2 percent of the population and is defined biochemically, by a suppressed thyrotropin with normal free T4 and free T3, so it cannot be identified by symptoms alone.

People whose primary complaint is adrenergic. Palpitations, tremor, heat intolerance and a fast resting pulse are the symptoms bugleweed has the best data for, and the Vonhoff rat work suggests the mechanism there is closer to beta-blockade than to hormone suppression.

Nobody who has not had a thyroid panel. Hyperthyroidism has a US prevalence of about 1.2 percent and an incidence of 20 to 50 cases per 100,000 per year, with Graves' disease accounting for 60 to 80 percent. The symptoms people self-treat with bugleweed, anxiety, palpitations, insomnia, weight change and heat intolerance, overlap almost completely with anxiety disorder, perimenopause, stimulant use and anemia. Third-generation thyrotropin receptor antibody assays reach 97 percent sensitivity and 99 percent specificity for Graves' disease. There is no reason to guess.

Who Should AVOID or Use Caution

Contraindications

• Hypothyroidism of any cause, including treated Hashimoto thyroiditis. This is the first line of the Commission E contraindication list and it appears on only 3 of the 37 on-market US labels.

• Thyroid enlargement without functional disturbance. A goiter with normal hormone levels is an explicit contraindication in the German monograph.

• Concurrent thyroid hormone therapy, which Commission E rules out directly.

• Pregnancy. The antigonadotropic activity is documented in animals, and no human pregnancy safety data exist.

• Breastfeeding. The prolactin-suppressing activity reported by Sourgens and colleagues in 1982 is the concern. The NIH Drugs and Lactation Database has no entry for bugleweed at all, which is not reassurance, it is absence.

• Children. German clinical guidance excludes those under 12, and no pediatric dosing has been established.

Use Caution

• Anyone scheduled for a thyroid uptake scan or radioiodine therapy. Normal 24-hour uptake runs about 8 to 25 percent, and 3 to 16 percent at 6 hours. Graves' disease raises it and thyroiditis lowers it, which is exactly the distinction the test exists to make.

• Anyone on antithyroid drugs. Methimazole is dosed at 5 to 40 mg daily by severity, with maintenance at 5 to 10 mg. An unmeasured second suppressant removes the clinician's ability to attribute a change to the dose they wrote.

• Anyone who has already started and wants to stop. Do not stop abruptly.

• Anyone with a nodular goiter, where functional status can change over time.

Critical Safety Point

The dangerous scenario is not an overdose. It is a person with fatigue, weight gain and cold intolerance buying a product named "Thyroid Support," a phrase that reads as help for an underactive gland, and taking a thyroid suppressant for months. Two such products in the label database, TerraVita's Thyroid Support 450 mg capsules and Thyroid Support Powder, contain bugleweed with motherwort and lemon balm at 1,350 mg per day of blend, list no individual ingredient amounts, and carry no thyroid caution of any kind.

Recommended Dosages

There is no established US dose. The numbers below are what regulators and trials actually used, not a recommendation.

Commission E, tea preparation. 1 to 2 g of dried herb per day.

Commission E, aqueous-ethanolic extract. Preparations equivalent to 20 mg of drug per day. Note the two-order-of-magnitude gap between this line and the tea line in the same monograph, which is a consequence of the auto-oxidation chemistry rather than an error.

Clinical trial dose, L. europaeus dry extract. 20 mg twice daily, 40 mg per day, in Beer and colleagues, Phytomedicine 2008, volume 15, pages 16 to 22, over three months.

Clinical practice study dose. Thyreogutt mono tablets or drops for four weeks in Eiling and colleagues, Wiener Medizinische Wochenschrift 2013, volume 163, pages 95 to 101.

North American herbal practice. 1:2 liquid extract at 2 to 6 mL daily, or 15 to 40 mL weekly. Tincture at 1:5 in 45 percent alcohol, 3 to 6 mL daily. Dried herb 3 to 9 g daily. Infusion of 1 to 2 g in boiling water for 10 to 15 minutes, three times daily. Naturopathic solid-dose guidance runs 100 to 400 mg two to three times daily, with 2 g or more per day reported as tolerated.

Duration

Four weeks is the shortest interval any study used and the minimum German practice guidance suggests before judging effect. Beer ran three months. Nothing longer has been formally studied, and the goiter risk in the Commission E side-effect line is tied specifically to prolonged use at high dose. Any course longer than four weeks should be paired with a repeat thyroid panel, which no US label suggests.

Timing & Administration

Liquid extracts dominate. Herb Pharm specifies one squeeze of the dropper bulb, 0.7 mL, in 2 ounces of water or juice, two to four times daily, best taken between meals. Hawaii Pharm and Herbal Terra specify 20 to 30 drops in 2 to 4 fluid ounces, up to four times daily. TerraVita's capsules are taken with meals.

Because levothyroxine is absorbed best on an empty stomach and is dosed 30 to 60 minutes before breakfast, no separation interval makes co-administration acceptable. The interaction is pharmacodynamic, not a matter of gut timing.

Three points follow from the chemistry rather than the marketing:

• Keep tinctures away from heat and light, which most labels do state. The active species are oxidation products of unstable phenolics, and potency drifts in both directions with age.

• Split the daily amount across two to four doses, which is what every label and both trials did.

• If a thyroid panel or an uptake scan is scheduled, stop well before it and tell the clinician in writing what was taken and for how long.

Timeline of Effects

Days 1 to 7. Nothing measurable should be expected in hormone values. In the Vonhoff rat model, co-treatment ran 5.5 weeks before the cardiac endpoints were read. Some people report calmer palpitations early, consistent with the adrenergic mechanism rather than a hormonal one.

Weeks 1 to 4. The interval Eiling and colleagues used. Across 403 patients with mild symptomatic hyperthyroidism, 146 prospective, 171 retrospective and 86 untreated controls, four-week responder rates were 72.6 percent, 96.5 percent and 41.2 percent respectively, where a responder had normalized thyroid values or at least a 20 percent reduction in symptom count. The 41.2 percent control rate is the number to hold onto: on a symptom-count endpoint over four weeks, four in ten people improve on nothing at all.

Three months. Beer's follow-up period. The measurable change was an increase in 24-hour urinary T4 excretion, p equals 0.032, with serum free T4 and thyrotropin unchanged.

A fair trial. Four weeks with a thyroid panel before and after. If neither the panel nor the symptoms have moved, the herb is not doing anything for that person.

When to conclude it is not working. If free T4 or free T3 is rising, or symptoms are escalating, at any point. Untreated hyperthyroidism is a moving target, and time on an unmeasured herb is time not spent on definitive treatment.

Benefits of Taking Bugleweed

Documented in humans, weakly. Two studies. Beer and colleagues, prospective, two-armed, open label, three months, in patients with a basal thyrotropin below 1.0 mU/L: increased urinary T4 excretion and reduced morning heart rate. Eiling and colleagues, open post-marketing surveillance across 403 patients: symptom improvement over four weeks against an untreated control cohort. Neither was randomized, blinded, or placebo-controlled.

Documented in animals. Reduced heart rate, blood pressure, hyperthermia, cardiac hypertrophy and beta-adrenoceptor density in thyroxine-treated hyperthyroid rats, at doses that did not shift thyroid hormone levels, with efficacy on receptor density close to atenolol's.

Documented in vitro. Complete, dose-related blockade of thyrotropin binding and adenylate cyclase stimulation in human thyroid plasma membranes; reduction of the thyrotropin-binding inhibitory activity of Graves' immunoglobulins; ultimately complete inhibition of extrathyroidal T4 5'-deiodination to T3 in rat liver microsomes.

Real activities that are not why anyone buys it. Rosmarinic acid from L. europaeus inhibits NADPH oxidase 4 with a half-maximal inhibitory concentration of 1 micromolar, in Molecules in 2018, volume 23, article 653. Two isopimarane diterpenes doubled the potency of tetracycline and erythromycin against Staphylococcus aureus carrying Tet(K) and Msr(A) efflux pumps, in Phytochemistry in 2003, volume 62, pages 83 to 87.

Potential Negatives & Side Effects

Iatrogenic hypothyroidism. The mechanism that makes the herb useful in hyperthyroidism makes it harmful in a euthyroid or hypothyroid person. Nobody has quantified how often this happens, because nobody is monitoring.

Thyroid enlargement. Commission E lists enlargement of the thyroid as a side effect of prolonged use at high dose, the expected consequence of chronic thyrotropin-axis interference.

Rebound on abrupt discontinuation. An increase in symptoms of thyroid overactivity has been reported after sudden discontinuation, and German practice guidance instructs both starting and stopping gradually. Sudden withdrawal has also been described as increasing prolactin secretion. The evidence here is monograph-level and clinical-report-level, not trial-level, and should be described that way.

Diagnostic interference. Covered in its own section below. It belongs in this list because a misread lab result is an adverse outcome even when the patient feels fine.

Reported minor effects. Headache, palpitations, tachycardia, nervousness and weight change appear in secondary sources. In Beer's trial of 62 participants, one adverse event was recorded, a subjective sense of cardiac rhythm disturbance. Eiling recorded none across 403 patients.

What is not documented. No hepatotoxicity signal, no nephrotoxicity signal, and no case series of bugleweed-induced myxedema in the indexed literature. The absence is meaningful in one direction only: with no monitoring requirement and no obligation to report, a slow drift into hypothyroidism is precisely the harm that generates no case report.

Deficiency Symptoms

Bugleweed is not an essential nutrient. There is no bugleweed deficiency, no dietary requirement, no reference intake and no biomarker of status. Nobody has ever become ill from not consuming Lycopus.

What bugleweed addresses

• Biochemically mild hyperthyroidism, meaning a suppressed thyrotropin with normal free hormone levels, in the population Commission E defined

• The adrenergic symptom cluster of thyrotoxicosis: palpitations, tremor, heat intolerance and tachycardia

• Breast tension and pain, the second Commission E indication, on animal antiprolactin data rather than clinical trials

Bottom line

The condition it addresses is a diagnosis, not a deficiency. It requires a thyrotropin measurement to establish and a repeat measurement to follow. An herb whose target condition can only be identified by a blood test should not be sold to people who have not had one.

Toxicity Symptoms

At high intake

Acute poisoning is not the failure mode. The documented high-dose consequence is thyroid enlargement with prolonged use, listed as an adverse effect in the Commission E monograph. Naturopathic sources report 2 g or more daily as tolerated, and Beer and Eiling together recorded one adverse event across 465 participants. The toxicity that matters is chronic and endocrine: sustained suppression of a gland in someone who did not need it suppressed.

Signs to reduce or stop

• Fatigue that worsens rather than improves, weight gain, cold intolerance, constipation, dry skin or slowed thinking, meaning the classic hypothyroid picture emerging on treatment

• A resting heart rate that drops below the person's normal range

• Visible or palpable enlargement at the front of the neck

• Any new thyrotropin value above the laboratory reference range

• A worsening of hyperthyroid symptoms shortly after stopping, which indicates rebound and calls for a supervised taper rather than a restart at full dose

General note

Preclinical safety work on L. europaeus dry extract published in Problems of Biological, Medical and Pharmaceutical Chemistry in 2020 found low acute toxicity, consistent with everything else in the record. Low acute toxicity in a compound with genuine endocrine activity is not a safety finding. It is the reason nobody notices.

How Bugleweed Works

Four mechanisms are documented, and they act at different points in the thyroid axis. Three are established in vitro or in animals. None has been confirmed as the operative mechanism in humans.

It modifies thyrotropin itself, rather than blocking the receptor. This is the finding most often stated incorrectly. Auf'mkolk, Ingbar, Amir, Winterhoff, Sourgens, Hesch and Ingbar reported in Endocrinology in 1984, volume 115, pages 527 to 534, that freeze-dried aqueous extracts of Lycopus virginicus, Lycopus europaeus, Melissa officinalis and Lithospermum officinale produced dose-related and ultimately complete inhibition of bovine thyrotropin binding to human thyroid plasma membranes, along with inhibition of adenylate cyclase activation. The follow-up in Endocrinology in 1985, volume 116, pages 1677 to 1686, established how: the oxidized plant phenolics form a high molecular weight adduct with thyrotropin. On Sephadex G-100 chromatography the labeled hormone shifted from an apparent molecular weight of about 30,000 to the void volume, and hormone recovered from those early fractions bound poorly to thyroid membranes. Preincubating the membranes with active oxidation products and then washing had no effect on subsequent binding. The plant modifies the hormone in the circulation, not the receptor on the cell.

It inhibits peripheral deiodination. Auf'mkolk, Köhrle, Gumbinger, Winterhoff and Hesch showed in Hormone and Metabolic Research in 1984, volume 16, pages 188 to 192, that aqueous extracts of Lycopus virginicus, Melissa officinalis and Lithospermum officinale inhibited both extrathyroidal T4 5'-deiodination to T3 and T4 5-deiodination in rat liver microsomes, dose dependently and ultimately completely. Activity rose after freeze-drying and fell after permanganate oxidation.

It lowers endogenous thyrotropin release. Winterhoff, Sourgens and Kemper, in Hormone and Metabolic Research in 1983, volume 15, pages 503 to 507, showed a freeze-dried extract given alone lowered endogenous thyrotropin in rats along with thyroidal secretion and circulating hormone, and blocked the endocytosis increase induced by exogenous thyrotropin. Onset was faster and duration longer than potassium iodide, which points away from simple iodide loading.

It reduces the receptor-binding activity of Graves' autoantibodies. In Endocrinology in 1985, volume 116, pages 1687 to 1693, active extracts decreased the thyrotropin-binding inhibitory activity of Graves' immunoglobulins dose-dependently and inhibited their biological activity. Extracts lacking antithyrotropic properties had minimal effect, which argues for specificity rather than a protein-precipitating artifact.

The activation requirement. Every one of these effects depends on oxidation. The 3,4-dihydroxycinnamic acid derivatives are inactive as isolated and become active only after auto-oxidation to quinone-type products. Gumbinger and colleagues showed in 1981 that the reaction between quinones and unoxidized diphenols, forming quinhydrones, generates the active species. Nahrstedt and colleagues isolated two cyclolignan derivatives from permanganate-oxidized caffeic acid in 1990, both antigonadotropic.

Selectivity. The 1984 work found the extracts also inhibited human chorionic gonadotropin binding but had no effect on insulin binding. The activity is directed at glycoprotein hormones, not at receptors generally.

What is not established. No human study has demonstrated any of these mechanisms at oral doses. Beer's trial found increased urinary T4 excretion with unchanged serum free T4 and thyrotropin, and the authors proposed a renal mechanism, altered glomerular handling or impaired reabsorption, that none of the in vitro work predicts. Vonhoff's cardiac results occurred without hormone changes at all. The receptor pharmacology is real and well characterized in the test tube, the human effect is real but small, and the connection between the two has not been shown.

Synergistic Supplements

Traditional practice combines bugleweed with two other Lamiaceae members, and the combination appears on real labels rather than only in textbooks.

• Motherwort (Leonurus cardiaca). The classic pairing for the cardiac symptoms of thyrotoxicosis. It appears with bugleweed in TerraVita's Thyroid Support, Herb Pharm's Thyroid Calming, and Herbalist and Alchemist's Thyroid Calmpound.

• Lemon balm (Melissa officinalis). Not merely a calming addition. Melissa was one of the four species in the original Auf'mkolk experiments and showed the same antithyrotropic activity as Lycopus. Combining them stacks one mechanism, which is the opposite of what "synergy" usually means on a label.

• Beta-blockers. Not a supplement, but worth stating: the rat data put the extract close to atenolol on cardiac beta-adrenoceptor density. Anyone already on propranolol for thyrotoxic symptoms is not adding a different mechanism.

What does not belong alongside it: kelp, bladderwrack, and any iodine-containing product.

Interactions & What NOT to Take

Levothyroxine, liothyronine and desiccated thyroid. Commission E instructs directly that Lycopus preparations not be given with thyroid hormone preparations. This is the most likely real-world interaction, because "thyroid support" products are bought by people already on replacement.

Methimazole and propylthiouracil. Additive suppression on top of a titrated dose. Methimazole carries its own risks at any dose, with hepatotoxicity reported in roughly 0.4 percent of patients and agranulocytosis in a smaller fraction. An unmeasured herbal addition makes dose-finding guesswork.

Radioiodine therapy and thyroid uptake scans. Lycopus preparations interfere with thyroid diagnostics using radioisotopes. Uptake studies separate Graves' disease from thyroiditis and set radioiodine treatment doses. Antithyroid drugs are held at least five days before an uptake study and iodinated contrast for weeks; there is no published washout interval for bugleweed, because nobody has established one.

Thyroid function tests in general. Any product that alters peripheral deiodination, thyrotropin release or thyrotropin binding changes the numbers the clinician reads. A patient who does not mention the herb hands their doctor an uninterpretable panel.

Prolactin-relevant drugs and fertility treatment. The prolactin suppression documented in rodents makes co-use with cabergoline or bromocriptine, and interpretation of a prolactin measurement, uncertain. Long-term use carries possible contraceptive effects through the antigonadotropic mechanism, and it is contraindicated for anyone attempting to conceive.

Beta-blockers. Additive effect on heart rate and blood pressure, on the rat evidence.

Quality, Testing & Adulteration

There is no compendial standard to test against in the United States. Commission E's monograph is a therapeutic document. It names indications, contraindications and doses, but specifies no marker compound and no assay. That is the only regulatory text most bugleweed sellers can point to, and it does not define quality.

Nothing on any label is verifiable. Across 75 DSLD records, zero declare a marker compound, zero declare a standardization percentage, and 42 do not name a species. A certificate of analysis for bugleweed can report microbial counts, heavy metals and pesticide residues, all of which matter, and still say nothing about whether the material has antithyrotropic activity, because no accepted assay for that exists outside a research laboratory.

The natural variability is large and measured. Bucar and Kartnig quantified luteolin 7-O-glucuronide by HPLC across crude methanolic extracts of L. virginicus, L. europaeus and L. exaltatus in Planta Medica in 1995, volume 61, pages 378 to 380. Content ranged from 0.017 percent to 0.22 percent, a thirteenfold spread across the genus. Rosmarinic acid measured 76 mg/g in the 2015 Slovak analysis. No commercial product reports either figure.

Species substitution is structurally invited. "Lycopus spp." on 29 of 75 records declares that the manufacturer either does not know or does not intend to say which species is in the bottle. L. virginicus, L. europaeus, L. americanus, L. exaltatus and L. lucidus are all in commerce somewhere, differ in phenolic content, and are not interchangeable in the literature. Lycopus lucidus, sold in Chinese medicine as ze lan, is used for blood stasis and swelling, not for the thyroid at all.

The name collision is real but separate. Ajuga reptans is sold in every garden center as bugleweed or carpet bugle. No authentication survey has looked for it in the supplement supply, but the shared common name is a hazard for anyone wildcrafting.

What a buyer can actually verify

• The Latin binomial and the plant part, printed on the label. Four of 75 records give it.

• The extract ratio and the herb equivalent per dose, so daily intake can be calculated rather than guessed.

• A certificate of analysis with identity confirmed by HPTLC or DNA against a named reference, plus heavy metals, microbial limits and pesticide residues.

• Whether the seller can name any marker compound at all. None currently does.

What no third-party program covers. Bugleweed does not appear among the botanicals USP publishes monographs for, no USP Verified or NSF certified bugleweed product exists, and no ConsumerLab report covers the category. The buyer is on their own, on a product with real endocrine activity.

Special Considerations

Regulatory asymmetry. In Germany, Lycopi herba is a drug with an official monograph carrying contraindications and interaction warnings. EFSA's Compendium of Botanicals, in the EFSA Journal in 2012, volume 10, article 2663, lists Lycopus spp. as a genus whose species may show an antihormonal effect on thyroid hormones, possibly at the hypophyseal level. The European Medicines Agency's Committee on Herbal Medicinal Products has never assessed it and ESCOP has issued no monograph. In the United States it is sold under the Dietary Supplement Health and Education Act of 1994, Public Law 103-417, which requires no premarket approval and no safety or efficacy demonstration for a botanical marketed before that year.

Structure and function claim latitude. Under 21 CFR 101.93, a manufacturer may claim a supplement supports a body structure or function, notify the FDA within 30 days, and print the disclaimer. That is how a 20-ingredient detox blend can carry the label line "Bugleweed supports the reduction of hyperthyroid symptoms," as Crystal Star's Toxin Detox does, while carrying no thyroid contraindication.

Bugleweed in blends nobody would associate with the thyroid. The label database shows it in Christopher's Heavy Mineral Bugleweed Formula, New Sun's 24-ingredient HRT Combination, Earth Friend Herb Co.'s 16-ingredient Heart-Ease, Herbalist and Alchemist's Reckless Blood Tonic, and Nature's Sunshine's Intestinal Soothe and Build. Someone taking a heart or menopause blend has no reason to suspect a thyroid suppressant is in it.

Adverse event reporting. Since the Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006, Public Law 109-462, manufacturers must report serious adverse events. A gradual slide into hypothyroidism over four months does not present as one, and will not be reported.

Research Status & Evidence Quality

Strong Evidence For

• In vitro inhibition of thyrotropin binding and adenylate cyclase stimulation in human thyroid membranes, replicated across two Endocrinology papers in 1984 and 1985 with a defined molecular mechanism

• In vitro inhibition of rat liver iodothyronine deiodinase, dose dependent and complete

• The oxidation requirement, established across 34 test compounds with a potency range of 20 to 80 micrograms per milliliter equivalent

Moderate Evidence For

• Reduction of cardiac signs of hyperthyroidism in an animal model, with beta-adrenoceptor density changes comparable to atenolol

• Reduction of the receptor-binding and biological activity of Graves' immunoglobulins in vitro

• Antigonadotropic and prolactin-suppressing activity in rodents

Emerging / Preliminary Evidence For

• Symptom improvement in mild human hyperthyroidism, on one open two-armed study and one surveillance study totaling 465 patients, neither randomized, blinded, nor placebo-controlled

• Increased urinary T4 excretion, a single finding at p equals 0.032 with a renal mechanism proposed after the fact and never replicated

• Breast tension and pain, an approved German indication with no clinical trial behind it

Research Limitations

• Zero randomized placebo-controlled trials exist. In 2026, more than four decades after the mechanism was characterized, the human evidence for a thyroid-suppressing herb sold to thyroid patients consists of two uncontrolled studies.

• Eiling's untreated control group improved at 41.2 percent on a symptom-count endpoint, which is exactly the effect size an open-label study cannot separate from its intervention.

• Human dosing does not correspond to the doses that produced the in vitro effects, and no pharmacokinetic study has established what reaches the circulation after an oral dose, or in what oxidation state.

• Almost every mechanistic paper used freeze-dried aqueous extracts prepared in a laboratory. No study has tested a retail American tincture.

• No safety data exist beyond three months, and no study has measured how often bugleweed causes hypothyroidism, the question a buyer most needs answered.

Summary & Key Takeaways

Bugleweed is not another herb whose marketing exceeds its pharmacology. It is a plant with reproducible, mechanistically characterized activity against the thyroid axis, sold in the United States without a dose standard, without a marker compound, without a monitoring requirement, and in most cases without a warning that it acts on the thyroid at all. Germany decided in 1990 that this material needed a drug monograph. The United States decided in 1994 that it needed a disclaimer.

Bottom Line

Credible pharmacology with thin human evidence is an unusual combination and a bad one. Two uncontrolled studies in 465 patients is not a basis for self-treating a condition whose complications include atrial fibrillation, at a relative risk of 3.1 in adults over 60 whose thyrotropin is below 0.1 mIU/L, hip fracture at a hazard ratio of 1.35, heart failure at 1.94, and thyroid storm with a mortality of 8 to 25 percent. The opposite error, drifting into hypothyroidism on an unmeasured suppressant, generates no case series because nobody is looking.

Key Safety Points

• Contraindicated in hypothyroidism, in goiter without hyperfunction, in pregnancy and lactation, and alongside thyroid hormone therapy

• Interferes with thyroid function testing and with radioisotope uptake studies, with no established washout period

• Should not be stopped abruptly; taper under supervision

• Only 3 of 37 on-market US labels warn about any of this, and none mentions blood tests

• A product named "Thyroid Support" containing bugleweed is a thyroid suppressant, whatever the buyer assumes

Special Note

The supplements worth the most scrutiny are not always the ones making the loudest claims. An inert herb with an inflated label costs money. An active herb with an unmeasured dose, acting on an organ where error in either direction has cardiac and skeletal consequences, costs something else. When a botanical's own mechanism paper runs in Endocrinology and its retail label names no species, no ratio and no marker, the gap between what is known about the plant and what is disclosed about the product is the whole story.